Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001A. Shaw, S.‐H.I. Ou, Yung‐Jue Bang et al.|Annals of Oncology|2019Cited by 587